Psychiatric News June 17, 2005
Volume 40 Number 12
© 2005 American Psychiatric Association
p. 32
Alzheimer's Drug Shows Some Cognitive Benefits
Jim Rosack
Two reviews suggest that memantine may be beneficial for patients with
moderate to severe Alzheimer's disease, especially those at risk for agitation
or aggression.
New reviews of clinical trials data suggest that memantine (Namenda) is
effective at slowing the progression of cognitive decline in patients with
moderate to severe Alzheimer's disease. However, for most patients that effect
may be small. After six months of treatment, patients given memantine had
slightly less functional and cognitive decline and were less likely to become
agitated compared with those given placebo.
A review by the Cochrane Collaboration in London of its Specialized
Register of the Cochrane Dementia and Cognitive Improvement Group pooled
clinical trials data and unpublished data of the drug's use in the treatment
of patients with moderate to severe Alzheimer's, mild to moderate Alzheimer's,
and mild to moderate vascular dementia. The review was published in the April
Cochrane Database of Systematic Reviews.
The Cochrane team found that memantine can slow down the rate at which
cognitive deterioration and loss of everyday functions typically occurs in
patients with moderate to severe Alzheimer's disease.
While the effect is small, it is "clinically noticeable,"
according to Rupert McShane, M.D., a professor of medicine at the University
of Oxford and lead author of the Cochrane review.
The studies reviewed by the team suggest some cognitive benefits from the
drug in patients with mild to moderate Alzheimer's or mild to moderate
vascular dementia. However, these changes were not judged clinically
significant in the studies reviewed, and "it remains unknown whether
there is a true benefit in mild to moderate cases," McShane and his
colleagues wrote.
In addition, the authors noted, there was no evidence that memantine was
effective for reducing agitation or aggression in dementia patients;
nonetheless, patients on the drug had lower rates of agitation and aggression,
which suggests a possible preventive effect.
Memantine is approved by the U.S. Food and Drug Administration only for the
treatment of moderate to severe Alzheimer's. The European Union's Agency for
the Evaluation of Medical Products approved the drug for a similar
indication.
Both agencies are reviewing applications by Forest Laboratories, the drug's
manufacturer, for approval of the drug for mild to moderate Alzheimer's.
The Cochrane review included nine studies with data on 2,339 patients.
However, the reviewers noted that three additional large studies have yet to
be published. Cochrane reviewers attempted to account for the data in those
studies by including information that was publicly available from the three
trials. They then calculated how the still unknown data would affect the
overall review in worst-case and best-case scenarios.
McShane and his colleagues acknowledged that firm conclusions may need to
await the full disclosure of the data and results of those additional trials.
While one study finished collecting data in 2003, "the lack of any
substantive reference to it suggests that the results may be less favorable
than those in published studies."
A second review, appearing in the May International Journal of
Geriatric Psychiatry, was more limited in scope. That review, completed
by Serge Gauthier, M.D., director of the Alzheimer and Cognitive Disorders
Clinic of the McGill Centre for Studies in Aging at McGill University in
Montreal, and colleagues compiled data from two randomized, controlled studies
on patients with moderate to severe Alzheimer's. They analyzed only the data
collected with the Neuropsychiatric Inventory (NPI).
The subjects received memantine in one study, and memantine and donepezil
in the other. The control groups in both studies, which had a total of 656
subjects, received placebo, and all lived in the community.
"In both studies, the change in NPI total scores at endpoint was
consistently in favor of memantine treatment, reaching statistical
significance in the combination study," reported the researchers.
Like the Cochrane reviewers, Gauthier and his colleagues noted that
memantine was associated with statistically significant less
agitation/aggression emerging in the subjects compared with those receiving
placebo.
An abstract of the "Cochrane Review: Memantine for
Dementia" is posted online at
<www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003154/abstract.html>.
An abstract of "Effects of Memantine on Behavioural Symptoms in
Alzheimer's Disease Patients: An Analysis of the Neuropsychiatric Inventory
(NPI) Data of Two Randomised, Controlled Studies" is posted at
<www3.interscience.wiley.com/cgi-bin/abstract/110478152/ABSTRACT>.
Get information about faster international access.
Privacy Policy
Copyright © 2005
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
| 
